Results 181 to 190 of about 2,312,760 (293)

Clinicopathological Characteristics of Acute Antibody-Mediated Rejection in Pediatric Liver Transplantation-A Single-Center Study. [PDF]

J Clin Med
Szymanska S, Piątosa B, Ciopiński M, Kijewski A, Kaliciński P, Markiewicz-Kijewska M.   +5 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Update on diagnostic and therapeutic strategies for antibody-mediated rejection in kidney transplantation. [PDF]

World J Transplant
Elahi T, Ahmed S, Mubarak M.
europepmc   +1 more source

Alamandine/MrgD pathway modulates gut–bone marrow axis in ageing

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ageing is associated with colon epithelial barrier disruption and up‐regulation of myelopoiesis in the bone marrow (BM). Alamandine (Ala) and MrgD are novel members of the renin angiotensin system (RAS). This study tested the hypothesis that Ala restores the colon epithelial barrier integrity in ageing via modulating gut–
Kishore Chittimalli, Henryata E. Rozario, Victor Martinez, Zachary L. McAdams, Stephen A. Adkins, Aaron C. Ericsson, Yagna P. R. Jarajapu   +6 more
wiley   +1 more source

Postpartum Triple Allograft Injury with Atypical Hemolytic Uremic Syndrome, Recurrent IgA Nephropathy, and Antibody-Mediated Rejection in a Kidney Retransplant Recipient: A Case Report. [PDF]

J Clin Med
Chen X, Wang D, Yang L, Qiu L, Zhou J.
europepmc   +1 more source

Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria

Cancer Science, EarlyView.
Spatial localization of intratumoral bacteria governs their functional roles in tumor progression, metastasis, and treatment responses, with guiding significance for clinical management, as reviewed across three spatial paradigms. ABSTRACT Bacteria in tumors are increasingly recognized to be a part of the tumor microenvironment and their biological ...
Minlan Ren, Jing Jia, Tingting Li, Yiwei Li, Nanxiang Shen, Yun Shi, Zhe Wang, Hao Fan, Guangli Sun, Guanying Xiong, Gang Li, Rui Peng   +11 more
wiley   +1 more source

Not all antibodies are created equal: total IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation. [PDF]

Transpl Int
Noble J, Glendenning LM, Dard C, Bourdin A, Crespo M, Maggiore U, Inwood AR, Carlson GC, Cobb BA, Cravedi P.   +9 more
europepmc   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source